Pfizer May No Longer be Able to Delay Paying Its Asbestos Claims of Nearly $1 Billion
Pfizer, which claims to be the "world's largest research-based pharmaceutical company," is one step closer to paying a nearly one billion dollar settlement of legal claims of harms due to the asbestos products it used to manufacture.Pfizer Settles - More or Less - Some of its Asbestos Liability Most people would not think of Pfizer as a producer of asbestos. However, the back-story, as reported in the Philadelphia Inquirer, and as we discussed here in 2011, is thatPfizer used to have a minerals, pigments and metals division and, in 1968, it bought Quigley Company Inc., which made insulation for heavy industry.Quigley...
Source: Health Care Renewal - June 28, 2013 Category: Health Medicine and Bioethics Commentators Tags: deception Quigley Pfizer mission-hostile management legal settlements asbestos Source Type: blogs
Coming To Terms With A Terminal Illness
Coping with a terminal illness is one of the most difficult things to do in life. It is incredibly difficult to cope; for the sufferer and their family and friends. There are a number of things to talk about, come to terms with and decide on; but of course, the first thing needs to be the process of coming to terms with the affliction.
Telling loved ones can be incredibly difficult, from everyone’s point of view. For those hearing the news it is obviously terrible to find out that a loved one has a terminal disease. Even for those who do the telling it can be difficult to bring somebody down and see the way they react.
C...
Source: Mental Nurse - July 31, 2012 Category: Nurses Authors: Iqcguest Tags: Mental health mesothelioma Terminal Illness Source Type: blogs
Breast Carcinoma vs. Pulmonary Adenocarcinoma
Some authors have estimated that 4-9% of patients with breast carcinoma will eventually develop second pulmonary carcinomas. As a result, many pathologists have been faced with the problem of trying to determine whether a particular lung carcinoma represents metastatic breast carcinoma or a new primary pulmonary adenocarcinoma. This month, we will briefly review antibodies that may be useful in addressing this differential diagnostic problem.GCDFP-15(gross cystic disease fluid protein-15): This marker has good specificity for breast carcinoma, although its sensitivity is not high, as only about 50% of breast carcinomas exp...
Source: Oncopathology - December 30, 2010 Category: Cancer & Oncology Tags: Breast Carcinoma vs. Pulmonary Adenocarcinoma Source Type: blogs
Work up of Carcinoma of Unknown Primary (CUP)
It is often important to determine the site of origin of a metastatic carcinoma of unknown primary site, particularly because this may affect the choice of the treatment. Determination of the primary site may take several steps.Clinical features, such as age, sex, and site of metastases may give a first indication.A detailed pathologic examination of the most accessible biopsied tissue specimen is mandatory in CUP cases. Pathologic evaluation typically consists of hematoxylin-and-eosin stains and immunohistochemical tests.Electron microscopy is rarely used currently, although it may beselectively useful when making treatme...
Source: Oncopathology - May 4, 2009 Category: Cancer & Oncology Tags: Work up of Carcinoma of Unknown Primary (CUP) Source Type: blogs
